The first BCMA-targeting antibody-drug conjugate for appropriate patients with relapsed/refractory multiple myeloma
BLENREP is composed of a humanized anti-BCMA monoclonal antibody conjugated to the cytotoxic payload MMAF by a protease-resistant linker.1,2
BLENREP specifically binds to B-cell maturation antigen (BCMA), a cell-surface protein expressed on myeloma cells, late-stage B cells, and plasma cells.1,3
A multimodal mechanism of action

Delivers cytotoxic payload1
Disrupts the microtubule network1
Engineered for enhanced ADCC and ADCP1,2

BLENREP may have an effect on normal cells.1,2

Specifically binds to BCMA:
Upon binding to BCMA on the cell surface, BLENREP is then internalized and releases a cytotoxin, mafodotin.1,2

Delivers a cytotoxic payload:
Mafodotin, a potent microtubule disruptor, prevents multiple myeloma cells from dividing, leading to apoptosis.1,4

Enhances immune-mediated actions:
BLENREP has an afucosylated antibody that enhances recruitment and activation of immune effector cell-mediated antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).1-3